Filing Details

Accession Number:
0001209191-13-048483
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-10-16 16:21:35
Reporting Period:
2013-10-14
Filing Date:
2013-10-16
Accepted Time:
2013-10-16 16:21:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1446372 M Paul Silva C/O Vertex Pharmaceuticals Incorporated
130 Waverly St.
Cambridge MA 02139
Svp & Corp Controller No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-10-14 468 $33.82 12,218 No 4 M Direct
Common Stock Acquisiton 2013-10-14 1,125 $51.75 13,343 No 4 M Direct
Common Stock Disposition 2013-10-14 214 $70.41 13,129 No 4 S Direct
Common Stock Disposition 2013-10-14 500 $71.57 12,629 No 4 S Direct
Common Stock Disposition 2013-10-14 754 $72.26 11,875 No 4 S Direct
Common Stock Disposition 2013-10-14 125 $73.22 11,750 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2013-10-14 468 $0.00 468 $33.82
Common Stock Stock Option (right to buy) Disposition 2013-10-14 1,125 $0.00 1,125 $51.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,407 2020-07-13 No 4 M Direct
7,875 2021-07-12 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 169 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $70.41 (range $70.00 to $70.85).
  3. Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $71.57 (range $71.00 to $71.93).
  5. Open market sales reported on this line occurred at a weighted average price of $72.26 (range $72.01 to $72.89).
  6. The option vests in 16 quarterly installments from 07/14/2010.
  7. The option vests in 16 quarterly installments from 07/13/2011.